Companion Biomarker Testing for IL-2 and MSC Therapy Risks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-2-based therapies for cancer and HIV treatment are associated with significant toxicities and adverse effects, and the impact of the local environment on mesenchymal stem cells (MSCs) during transplantation is not well understood, necessitating methods to predict and mitigate potential adverse events.
Innovation Solution
Developed methods and kits to determine the expression levels of biomarkers indicative of cellular senescence in individuals and MSCs, allowing for the prediction of adverse events such as tumorigenesis or metastasis, thereby guiding treatment decisions for IL-2-based therapies and MSC transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL-2 therapy is administered to treat cancer, then overall response rates are achieved, but significant toxicities affect every organ system requiring hospitalization and intensive care
Solution Approach 1:
The patent applies preliminary action by measuring biomarker expression levels (such as VEGF, ANGPTL2, and other angiogenesis-related markers) before initiating IL-2 therapy to predict which patients are at risk for severe toxicities. This allows clinicians to pre-identify suitable candidates and take preventive measures, such as selecting alternative therapies or implementing monitoring protocols, before the harmful effects manifest.
Solution Approach 2:
The patent implements feedback by using companion diagnostic methods to measure biomarker expression levels in response to IL-2 stimulation. The results provide feedback on the patient's likely response and toxicity risk, allowing for real-time adjustment of treatment decisions. This feedback loop enables personalized medicine approaches where treatment continues only for patients showing favorable biomarker profiles.
2Productivity
If mesenchymal stem cells are transplanted in a pro-inflammatory environment, then cell-based therapy is delivered, but unwanted adverse events occur due to environmental effects on the transplanted cells
Solution Approach 1:
The patent applies preliminary action by assessing the local tissue environment and biomarker profile before MSC transplantation. By measuring inflammatory markers and angiogenesis factors in the target tissue, clinicians can predict whether the environment is suitable for MSC transplantation. This allows for pre-treatment preparation, such as reducing inflammation or selecting alternative transplant sites, to prevent adverse events before they occur.
Solution Approach 2:
The patent uses biomarkers as intermediaries to mediate between the complex pro-inflammatory environment and the transplanted MSCs. By measuring specific biomarker expression patterns, the system indirectly assesses the environmental suitability for MSCs without directly manipulating the inflammatory environment. This intermediary approach provides a safe way to evaluate and predict MSC behavior in challenging environments.
3Reliability
If biomarker expression is monitored to predict adverse events, then treatment safety is improved, but additional testing time and complexity are required
Solution Approach 1:
The patent applies universality by developing companion diagnostic methods that can assess multiple parameters (angiogenesis markers, inflammatory markers, cell proliferation markers) using a single integrated approach. The same biomarker panel serves multiple functions: predicting toxicity risk, evaluating treatment response, and monitoring disease progression. This multi-functionality reduces the need for separate specialized tests and simplifies the overall diagnostic workflow.
Data Source
Figure 1A
Figure 1B
Figure 2A~2B
AI summary
Described herein are companion methods and kits useful for IL-2-based therapies and for mesenchymal stem cell-based therapies, in particular in determining risk of adverse events (such as angiogenesis) associated with IL-2-based therapy, using biomarkers expression level.